Apretude

Understanding Apretude®

Apretude® (cabotegravir) is a long-acting injectable medication used for pre-exposure prophylaxis (PrEP) to prevent HIV infection in people at high risk. As the first and only injectable PrEP option, Apretude® offers a highly effective alternative to daily pills by providing sustained protection through periodic injections. This innovative treatment improves adherence, offers a discreet and convenient option, and is ideal for individuals who struggle with daily PrEP regimens and desire a low-maintenance HIV prevention strategy.

How Apretude® Works:

  • Prevents HIV infection by blocking viral replication before exposure.
  • Provides long-lasting protection with injections every two months.
  • Eliminates the need for daily pills, enhancing adherence and convenience.

FDA Approval:

  • Apretude® (cabotegravir): Approved in December 2021.

For more information, please visit the Apretude® patient website and speak with your healthcare provider to determine if Apretude® is the right prevention option for you.

Referral Form

What it Treats

Manufacturer

GlaxoSmithKline

Class

HIV PrEP

Prescribed by

How Administered

Subcutaneous Injection

Frequency

Monthly for two consecutive months, then every other month.

Length of infusion

30 mins

Other Treatments

Get in touch

Phone

732 931 4633
732 413 2421 (FAX)

Address

Monmouth County
Long Branch, NJ 07740